A Multi-center, Prospective Cohort, Observational Study to Evaluate the Incidence of Major Adverse Cardiocerebrovascular Events According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received Dual AntiPlatelet Therapy (DAPT) for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
Latest Information Update: 11 Aug 2022
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Esomeprazole (Primary)
- Indications Gastrointestinal haemorrhage
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 11 Aug 2022 New trial record